Fuse Biotherapeutics
- 30/11/2021
- Seed
- $9,500,000
At FuseBio, we are dedicated to developing transformative immune modulating therapeutics for patients with cancers. Our therapeutic approach integrates the multiple steps of an immune response in a rational manner such that potent responses to danger are targeted without sacrificing natural breaks in the system that spare healthy tissues.
- Industry Biotechnology
- Website https://www.fusebiotx.com/
- LinkedIn https://www.linkedin.com/company/fusebiotx/
Related People
Paul Y. Song, MDCo Founder
Board Certified Radiation Oncologist. Experienced Biotech Executive and Chief Medical Officer with a demonstrated history of working in the biotechnology and medical industry. Skilled in Management, Translational Medicine, Clinical Trials, Regulatory Affairs, Medical Devices, Diagnostics, Oncology, Immunology, Governmental Affairs, Therapeutic Development, and Healthcare Policy. Strong healthcare services professional graduated from University of Chicago.